Archive restoration — 26 September 2026: This article has been restored from our original source files. Its publication date and reporting context remain unchanged; it is not a new update on current policy, availability or clinical guidance.
The United States Drug Enforcement Administration has now made its closing argument for moving cannabis from Schedule I to Schedule III. That is significant. It is not the same thing as rescheduling cannabis.
The distinction matters because headlines can turn a procedural milestone into a finished policy. After a multi-week administrative hearing, post-hearing briefs were due on 17 August.[2] Reporting on the DEA’s filing says the agency asked the presiding administrative law judge to recommend Schedule III, reflecting the federal finding that cannabis has a currently accepted medical use and does not fit Schedule I’s criteria.[4]
The judge must still evaluate the record and issue a recommended decision. The federal government must then complete the rulemaking process before a broader change takes effect. Until that happens, patients, researchers and businesses should not behave as though federal cannabis law has already been rewritten.
Even so, an enforcement agency publicly defending Schedule III in its final brief marks a genuine change in the centre of American cannabis policy.
What the hearing was deciding
The hearing began on 29 June and ran into July. Its purpose was to test the federal proposal to move marijuana from Schedule I to Schedule III under the Controlled Substances Act.[1]
Schedule I is reserved for drugs deemed to have no currently accepted medical use in the United States, a high potential for abuse and no accepted safety for use under medical supervision. Schedule III substances remain controlled but are recognised as having accepted medical use and a lower abuse potential than drugs in Schedules I and II.
That is not legalisation. Schedule III would not create a general right to possess or sell cannabis, erase state-federal conflicts or convert dispensary products into FDA-approved medicines. It would change the federal classification and the legal assumptions attached to it.
The hearing was unusually important because it placed the evidence and objections into a formal record. Witnesses and participants could challenge the scientific, medical and procedural basis for the proposal. The administrative law judge’s task is not to decide whether cannabis is socially popular or whether state markets should exist. It is to apply the statutory scheduling criteria to that record.
The DEA’s June announcement described the proposed move as one based on the Department of Health and Human Services’ medical and scientific evaluation, including its conclusion that marijuana has a currently accepted medical use.[1]
What changed before the hearing ended
In April, the Justice Department completed a narrower federal action that has caused understandable confusion.
The department placed FDA-approved marijuana products and certain qualifying state-licensed medical-marijuana products into Schedule III.[3] That action did not broadly move all marijuana out of Schedule I. It created defined categories with specific conditions while leaving the larger proposed rule to proceed through the administrative hearing.
This means two things can be true at once:
- a limited group of qualifying products is already treated under Schedule III; and
- the nationwide rescheduling proposal covering marijuana more broadly is still unfinished.
The difference is not academic. Product qualification, prescription status, state licensing and federal conditions determine whether the April action applies. Someone buying cannabis from a state-legal shop should not assume that the product has become federally lawful simply because it was sold in a medical market.
Likewise, the existence of the pending rule does not protect conduct that remains prohibited today.
Why the DEA’s final position matters
For decades, Schedule I gave federal cannabis policy a circular quality. Cannabis was said to lack accepted medical use, while its classification made conventional research and medical integration harder. State programmes expanded around that federal position rather than because it had changed.
The DEA’s reported closing argument does not resolve every contradiction, but it changes who is carrying the burden. The agency responsible for administering the Controlled Substances Act is now asking its own judge to recognise that the statutory basis for Schedule I is no longer met.[4]
That carries more weight than a campaign promise or a congressional press conference. It places the administration’s position inside the formal record on which the recommended decision will be based.
Opponents have also filed closing arguments. Reporting on the briefs says some challenged the medical-use finding and raised concerns including workplace and transport drug testing.[4] Those concerns will not disappear merely because the DEA supports Schedule III. A judge is expected to address competing evidence and legal arguments, not count supportive headlines.
The outcome therefore remains uncertain in timing and detail even if the administration’s preferred destination is clear.
What Schedule III could change
The most immediate commercial consequence would concern federal tax.
Section 280E of the US tax code prevents businesses trafficking in Schedule I or II substances from deducting ordinary business expenses. If marijuana is broadly placed in Schedule III, state-licensed cannabis businesses are expected to become eligible for normal deductions. That could materially improve the finances of legal operators.
Research could also become easier in some respects. Schedule III substances remain controlled, and cannabis studies would still face FDA, DEA and institutional requirements, but the classification would better reflect accepted medical use and could reduce some of the exceptional burden created by Schedule I.
For medicine, the symbolic and institutional change may be larger than the immediate practical one. Rescheduling would formally reject the federal claim that cannabis has no accepted medical use. It could encourage more standardised products, clinical trials, insurance discussions and professional education.
But Schedule III would not automatically:
- approve cannabis flower or dispensary products as medicines;
- require insurers to pay for them;
- permit interstate commercial sales outside federal law;
- overturn convictions or expunge records;
- eliminate employer drug-testing policies;
- allow anyone to prescribe any cannabis product;
- replace state rules with one national medical programme.
Those outcomes would require separate laws, regulatory decisions or product approvals.
Patients should not be sold a legal shortcut
The medical language around rescheduling can make it sound as though every state cannabis product is about to receive a federal endorsement. That is inaccurate.
FDA approval remains product-specific. It requires evidence about composition, dose, safety, efficacy and manufacturing quality for a defined use. Moving a substance to Schedule III is a classification decision, not a marketing authorisation for every formulation containing it.
Patients in state programmes may eventually experience indirect benefits: more research, better professional guidance, improved business stability and possibly broader acceptance among clinicians. None is guaranteed on the day a rule changes.
Federal rescheduling would also leave a sharp difference between medical recognition and the continued criminalisation of activity outside authorised pathways. That tension should be discussed honestly. A policy can be a major reform and still be incomplete.
For UK readers, the US decision would not alter British prescribing law. Its influence would be scientific, commercial and political. American research capacity and investment shape the evidence available elsewhere, so a less restrictive federal framework could have international effects over time.
What happens next
The administrative law judge must review the hearing record and the final briefs, then issue a recommended decision. A recommendation is influential but not necessarily the last word. The responsible federal authority must publish a final rule before broad rescheduling takes effect, and litigation may follow.
There is no safe basis for promising a final date.
Readers should look for three concrete documents rather than relying on political summaries:
- the judge’s recommended decision;
- the final federal rule, including its scope and effective date;
- implementation guidance explaining which products and activities fall within the new classification.
Until those exist, “DEA supports Schedule III” is accurate. “Cannabis is now Schedule III nationwide” is not.
The editorial view
The DEA’s final brief appears to bring the United States closer than ever to ending cannabis’s blanket Schedule I status. That deserves to be recognised without turning anticipation into fact.
Schedule III is neither a cure-all nor a cosmetic change. It could correct a scientifically and medically untenable classification, reduce a punitive tax burden and give research a more rational foundation. It would also leave much of federal prohibition intact.
The better test is not whether rescheduling satisfies every constituency. It is whether federal law becomes more honest about accepted medical use while creating room for better evidence and safer products. On that measure, Schedule III would be progress.
The process now needs the same thing cannabis policy has often lacked: precision. Officials should publish the decision promptly, explain its limits in plain language and avoid allowing a maze of exceptions to replace one blunt rule with another.
For now, this is a turning point in the argument—not the final line of the law.
Key takeaways
- The DEA has reportedly asked its administrative law judge to recommend moving marijuana from Schedule I to Schedule III.
- Post-hearing briefs were due on 17 August after a hearing that began on 29 June.
- A separate April action moved only FDA-approved marijuana products and certain qualifying state-licensed medical products into Schedule III; it was not blanket rescheduling.
- The judge must still issue a recommended decision and the federal government must complete a final rule before a broader change takes effect.
- Schedule III would recognise accepted medical use and could remove the federal 280E tax penalty from state-licensed cannabis businesses.
- It would not legalise adult use nationwide, approve every dispensary product, erase convictions or automatically change workplace drug testing.
- Patients and businesses should wait for the judge’s recommendation, final rule and effective date before treating the proposal as law.
Sources
- DEA Hearing on Proposed Marijuana Rescheduling Begins June 29 — Drug Enforcement Administration
- Order Setting the Post-Hearing Brief Deadline — Drug Enforcement Administration
- Justice Department Places Qualifying Marijuana Products in Schedule III — US Department of Justice
- DEA and Opponents File Final Rescheduling Briefs — Marijuana Moment
